(firstQuint)A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD).

 Primary Objective: To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD).

 Secondary Objectives: To determine the single and multiple oral dose pharmacokinetics of SMT C1100 and its metabolites in patients with DMD.

.

 A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)@highlight

The purpose of this study is to determine whether increasing doses of SMT C1100 are safe, well tolerated and achieve appropriate blood levels in patients with Duchenne Muscular Dystrophy (DMD).

